Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus. The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXIâ„¢ provides complete protocol support for AXI3â„¢, AXI4â„¢, AXI4-Liteâ„¢, AXI4-Streamâ„¢, ACEâ„¢, ACE-Liteâ„¢ , AHBâ„¢ and APBâ„¢ interfaces. ... Synopsys® VC ...
Ever since the COVID-19 pandemic began to ease, Moderna has weathered a sharp revenue downturn. But a new FDA approval shows that the company's scientific engine is no one trick pony. Moderna's ...
The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV, making this the company’s second licensed product.
Credit: Moderna. The approval was based on data from the phase 3 ConquerRSV trial, which included approximately 37,000 adults 60 years of age and older. The Food and Drug Administration (FDA) has ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA ...